To determine what Americans know—and think they know—about prostate cancer, the PCF surveyed more than 2000 adults in the United States and uncovered some misperceptions that might prevent men who are at risk from accessing screening.
Forty-two percent of men say fear and dread of discomfort are two of the main reasons they do not to get screened for prostate cancer, according to a new report from the Prostate Cancer Foundation (PCF). However, most might be surprised to know that initial prostate cancer screening could be a simple blood test.
To determine what Americans know—and think they know—about prostate cancer, the PCF surveyed more than 2000 adults in the United States. The report, titled PCF 3P Report 2018: Public Perception of Prostate Cancer, uncovered some misperceptions associated with preventing men who are at risk from accessing screening.
Among the adults surveyed, for example, 68% of the men agreed that they would be more likely to go for prostate cancer screening if they knew they could start with a blood test.
Nurses and other health care professionals are perfectly positioned to correct misperceptions and share important facts about prostate cancer screening. In honor of Prostate Cancer Awareness month, consider sharing some surprising facts with patients and friends, and encouraging them to learn more about prostate cancer, risk factors, and screening.
The PCF’s eye-opening statistics reveal several emotional reasons for men’s reluctance to screen for prostate cancer. Raising awareness about the process and risk factors could alleviate some of those fears and encourage important conversations with providers.
Reference
The Prostate Cancer Foundation. PCF 3P Report 2018: Public Perception of Prostate Cancer. PCF Website. pcf.org/wp-content/uploads/2018/08/PublicPerception_PCF.pdf. 2018. Accessed Sept. 28, 2018.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.